Evidence map›Paper›PMID 40333248›Full record

ArticleVaccines2025

Vaccination Against RhoC in Prostate Cancer Patients Induces Potent and Long-Lasting CD4

Sara Fresnillo Saló, Juliane Schuhmacher, Anne Rahbech, Sara Ram Pedersen, Tina Seremet, Valero Andreu Matillas, Anna Schöllhorn, Andreas Røder, Steffen Wad Jørgensen, Klaus Brasso and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Vaccines, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Sara Fresnillo SalóNational Center for Cancer Immune Therapy, Department of Oncology, University Hospital Herlev, 2730 Copenhagen, Denmark.ORCID 0009-0002-6869-7337
Juliane SchuhmacherInstitute for Immunology, University of Tübingen, 72076 Tübingen, Germany.
Anne RahbechNational Center for Cancer Immune Therapy, Department of Oncology, University Hospital Herlev, 2730 Copenhagen, Denmark.ORCID 0000-0003-0590-7560
Sara Ram PedersenNational Center for Cancer Immune Therapy, Department of Oncology, University Hospital Herlev, 2730 Copenhagen, Denmark.
Tina SeremetNational Center for Cancer Immune Therapy, Department of Oncology, University Hospital Herlev, 2730 Copenhagen, Denmark.
Valero Andreu MatillasInstitute for Immunology, University of Tübingen, 72076 Tübingen, Germany.
Anna SchöllhornInstitute for Immunology, University of Tübingen, 72076 Tübingen, Germany.ORCID 0000-0001-7928-7312
Andreas RøderDepartment of Urology, Copenhagen Prostate Cancer Center, Rigshospitalet, University of Copenhagen, 2100 Copenhagen, Denmark.
Steffen Wad JørgensenRhovac ApS, Agern Allé 3, 2970 Hørsholm, Denmark.
Klaus BrassoDepartment of Urology, Copenhagen Prostate Cancer Center, Rigshospitalet, University of Copenhagen, 2100 Copenhagen, Denmark.ORCID 0000-0001-6562-6416
Cécile GouttefangeasInstitute for Immunology, University of Tübingen, 72076 Tübingen, Germany.ORCID 0000-0002-6410-2378
Per Thor StratenNational Center for Cancer Immune Therapy, Department of Oncology, University Hospital Herlev, 2730 Copenhagen, Denmark.
On Behalf Of The RhoVac-Study Group

Funding

RhoVac Aps no number
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

cancer vaccineCD4+ T cellsRhoC

Identifiers

PMID40333248
PMCPMC12031432

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.